Karuna Therapeutics submits NDA to FDA for schizophrenia treatment
Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia.
The NDA submission is supported by safety and efficacy data from the EMERGENT programme which assessed KarXT as a treatment for schizophrenia. This programme includes three completed positive trials, EMERGENT-1, EMERGENT-2 and EMERGENT-3, and the ongoing EMERGENT-4 and EMERGENT-5 trials assessing the drug’s long-term safety.
In the three completed trials, KarXT met its primary endpoint, and demonstrated a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo. The drug also met its secondary endpoints of reductions in both positive and negative symptoms of schizophrenia as measured by PANSS positive, PANSS negative and PANSS negative Marder factor subscales, in all three completed trials.
The drug was generally well tolerated with most adverse events being cholinergic in nature and rated mild to moderate in terms of severity.
Bill Meury, president and chief executive officer of Karuna Therapeutics, commented: “Schizophrenia is a serious mental illness that affects how one thinks, feels and behaves, with symptoms often appearing in patients in early adulthood, during the prime years of their lives. While current therapies have made a difference for many patients, they are not without limitations due to lack of full symptom relief or side effects that may lead to treatment discontinuation. KarXT, if approved, will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”
Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its …
Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and …
FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System
Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device …